SC99 is an orally active, selective STAT3 inhibitor targeting JAK2-STAT3 pathway by docking into the ATP-binding pocket of JAK2, also inhibits phosphorylation of JAK2and STAT3 with no effects on the other kinases associated with STAT3 signaling.
[1] Zhang Z, et al. Oncotarget. 2016 Feb 23;7(8):9296-308. [2] Xu Z, et al. Acta Pharmacol Sin. 2017 May;38(5):651-659.
















